# PHENIX (NCT02642471)

> Sentinel Lymph Node Biopsy Versus Pelvic Lymphadenectomy in Early-stage Cervical Cancer (PHENIX/CSEM 010)

No report yet. It can be ordered.

- Drugs tested: none (the trial tests a strategy, not a drug)
- Indication: early-stage cervical cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02642471
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Sun Yat-sen University
- Conditions: Cervical Cancer; Surgery; Quality of Life
- Interventions: no systematic pelvic lymphadenectomy
- Enrollment: 1080
- Primary outcome: Disease free survival in PHENIX-I
- Primary outcome: Disease free survival in PHENIX-II

## Some of the questions raised in the 13 indexed sources

_Automated from all 13 indexed sources (Oct 2021 – Oct 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- Whether sentinel node biopsy alone matches added pelvic lymphadenectomy for disease-free and cancer-specific survival
- Whether omitting lymphadenectomy reduces lymphedema, lymphocyst and other surgical morbidity
- Whether sentinel node biopsy alone should replace pelvic lymphadenectomy in early-stage cervical cancer practice
- Whether the comparison holds in both the SLN-negative and SLN-positive cohorts

## Indexed commentary on PHENIX so far

Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 8 posts on X
- 4 YouTube videos
- 1 podcast episode

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=phenix-nct02642471

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02642471", "email": "<work email>"}; the inbox owner confirms by the emailed link.
